PhorMed (Equity)
Funding Details
- Awarder
- StartEngine
- Date Award
- August 18, 2022
- Vertical
- Biotech
- Funding URL
- View Funding Page
- Valuation
- $51,650,000
- Funding Amount:
- $239,925,500,000
Company Info
- Founding Year
- 2024
- Traction
- PhorMed has raised over $2.5 million, gained more than 4,100 total shareholders, and has over 8,800 followers. They have completed Phase 1 trials and are preparing for Phase 2 trials.
- Organizations Involved
- None
- Founders
- Prof. Richard L. Chang, Ben Chang, Carole A. Salvador
- Company Description
- PhorMed is a Biotech Company specializing in Gene Repair Therapy, particularly with their lead drug RP-323. They aim to treat various disorders such as Parkinson’s disease, Acute Myeloid Leukemia, Hodgkin’s Lymphoma, and Acute Respiratory Distress Syndrome caused by COVID-19.
- Market
- Healthcare
- Location
- Century City, CA, US
- Coinvestors
- None